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DOES STORED HPC, APHERESIS PRODUCT NEED AN EXPIRATION DATE?
GRAFT CELL VIABILITY AFTER LONG TERM STORAGE
Merchant, M.1, Huang, W.2, Olszewski, M.2, Kletzel, M.1,2 1Northwest-
ern Memorial Hospital & Feinberg School of Medicine, Chicago, IL;
2Children’s Memorial Hospital & Robert H Lurie Comprehensive Cancer
Center, Chicago, IL
Background: Regulatory & accrediting organizations require that
stored HPC products be labeled with an expiration date. Stem Cell
Transplant Program at Children’s Memorial Hospital has been col-
lecting HPC, Apheresis products since 1992 with signed donor con-
sent for storage and discard. Though products were labeled with a 5
year expiration date, cells were not discarded until 2006, for want of
storage space.We identified 54 products which could be discarded as
their intended recipients had died. Products were in liquid nitrogen
storage for a period of upto 15.2 yrs. Cells were thawed & viability
testing done, as per written procedure.
Objective: We undertook this opportunity to discard products to
document effect of long term storage on graft cell viability.
Method: Donor products were collected by HPC, Apheresis be-
tween 1992 & 2003. Pre-freezing viability done using Trypan Blue
Dye Exclusion test was between 96-100% (median 97.3%). Products
were mixed with equal quantity of cryoprotectant [3 parts TC-199
without phenol red and 2 parts each of 10% Dimethylsulfoxide
(DMSO) and Autologous serum]. Heparin was used as anti-coagu-
lant. Cells were frozen using a controlled rate freezing program
and stored in liquid nitrogen. Product bags were thawed in a water
bath between 37 - 40oC, gently kneading the contents. Post thaw
samples were re-tested for viability, using Trypan Blue. Statistical
evaluations were done on SigmaStat 3.5.
Result:
Table 1.
Years in # of Viability Viability Pearson’sStorage Products Range Median P-vlaue Correlation (R)Total (0.1- 15.2) 54 68- 99 90.29% 0.484 -0.09720.1- 5.0 27 77- 97 91.03% 0.478 -0.1425.1- 10.0 12 68- 98 88.58% 0.526 -0.20410.1- 15.2 15 79- 99 90.33% 0.723 -0.0999Post thaw median viability was 90.3% (range68- 99%). Of 54 prod-
ucts, 37 products (69%) had viability. 90%; 51 (94%) had viability
. 80%; only 3 (6%) had viability below 79%.
15 products (28%) were in storage for \ 3.0 yrs; 12 products
(22%) for 3.1 to 5.0 yrs; 12 products (22%) for 5.1 to 10.0 years;
& 15 products (28%) were stored for . 10.1 yrs. Statistical evalua-
tions revealed no significant relationship between storage time &
cell viability.
Discussion: Total nucleated cell viability was measured as an indi-
cator of graft composition. 94% of products retained a viability of
. 80% on long term storage. Difference in pre freezing & post
thaw median vibility (7%) can be attributed to the freezing process
itself. Since HPC, A grafts are capable of engraftment regardless of
storage time or percentage of viable cells, stored HPC, A products
may actually have a long expiration period.
Conclusion: Long term storage of HPC, A products in liquid nitro-
gen does not result in any significant cell loss and may not need an
expiration date.180
IMMUNOMAGNETIC SELECTION OF CD81 MEMORY CELLS FOR THERA-
PEUTIC APPLICATIONS
Armstrong, R.1, Lowsky, R.2, Strober, S.2, Sheehan, K.1 1Stanford Hospi-
tal & Clinics, Stanford, CA; 2Stanford University, Stanford, CA
Infusion of allogeneic T cells, administered as donor leukocyte in-
fusions (DLI), has widespread acceptance as immunotherapy for re-
lapsed disease after BMT and as a means of increasing donor
chimerism in allogeneic recipients experiencing graft resistance.
However, recipients of DLI are at risk of GVHD primarily due to
the presence of alloreactive CD45RA1 naive T cells in the infused
cells and DLI is not an option for patients who develop GVHD
post-transplant. Mouse models indicate that GVHD results primar-ily from naive donor T cells whereas T cells expressingmemory phe-
notypes appear to promote donor chimerism without GVHD. To
assess the feasibility of isolating CD81memory cells from apheresis
collections as an alternative to standardDLI, a tandem immunomag-
netic selection strategy was used with CD45RA depletion followed
by CD8 enrichment. The resulting cells were predominantly
CD81/CD45RO1/CD441/CD49d1/CD62L- indicating an ef-
fector memory (TEM) subset. Cytokine secretion by in vitro stimula-
tion with third party cells showed the selected cells produced high
levels of IFNg and TNFa but little detectable IL-2, IL-4, or IL10
consistent with the effector memory classification. Post-selection re-
covery was typically. 200x106 cells providing doses of CD81mem-
ory cells comparable to their representation in high dose DLI. A
clinical trial to assess the effectiveness of these cells to improve donor
chimerism in patients showing graft resistance is planned.181
MOBILIZATION OF CD341 CELLS WITH GRANULOCYTE COLONY STIMU-
LATING FACTOR (GCSF) VERSUS GCSF PLUS PLERIXAFOR IN PATIENTS
WITH PRIMARY IMMUNODEFICIENCY DISORDERS (PIDS) UNDERGOING
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL (PBSC) COLLECTION
Kang, E.M.1, Yau, Y.Y.2, Maxwell, S.1, DeRavin, S.S.1, Borge, P.D.2,
Malech, H.L.1, Leitman, S.F.2 1National Institutes of Health, Bethesda,
MD; 2National Institutes of Health, Bethesda, MD
Peripheral bloodCD341 hematopoietic stem cell (HSC)mobiliza-
tion with GCSF is the established method for PBSC collection. In
2009 the FDA approved Plerixafor, a CXCR4 antagonist, to enhance
mobilization in patients with myeloma and lymphoma. Many patients
with PIDs mobilize poorly, limiting autologous PBSC-based treat-
ments. We therefore added plerixafor to our standard mobilization
regimen of GCSF, 10 mcg/kg daily for 5 days. Peripheral CD34
counts were assessed on days 4 and 5, and a day 4 CD34 count\
20 cells/uL was used as criteria for addition of plerixafor 240 mcg/
kg 11 hours prior to apheresis. Targeted CD341 yield was 4  106
cells/kg. From 1998 to 2010, 28 PID patients, underwent 48 mobili-
zation cycles (1-6 cycles/patient) during which 83 collections were
performed (1-3 aphereses/cycle). 16 of 28 patients received GCSF
only during 36 mobilization cycles, undergoing 68 procedures (1.9
procedures/cycle, range 1-3). Mean (6SD) circulating CD34 count
on day 5 was 31625 cells/uL (range 2-141) and day 5 product content
was 2236208  106 CD341 cells, for a cell dose of 4.764.3  106
CD34/kg (range 0.3-18). During 16.464.7 liters processed (LP),
mean procedure yield was 13.5610 106CD341 cells/LP. 3 patients
had such poor mobilization that further apheresis was considered fu-
tile. Since adding plerixafor, 9 of 13 mobilizations met criteria for its
use. In these, the day 5CD34 count was 57634 cells/uL (range 15-98)
and the day 5 product had 3426295  106 CD341 cells (range 55-
842), for a cell dose of 9.968.2  106/kg (range 2.2-24). During
15.767.1 LP, mean yield was 20.9614.0  106 CD341 cells/LP. 3
patients underwent initial mobilization with GCSF alone, then with
plerixafor on a subsequent cycle. In one patient, day 5 CD34 counts
were 11 vs 25/uL, respectively, and apheresis yields were 110 vs 231
x106 CD34s (5 vs 11.6 x106 CD341 cells/LP, and 1.6 vs 3.1  106
CD341 cells/kg). In patient two, the day 5 CD34s were 2 vs 15/uL,
and product contents were 9 vs 55  106 CD34s (0.4 vs 2.2 
106CD34/kg). The third patient had undergone multiple GCSF mo-
bilizations, resulting in a mean day 5 CD34 of 41/uL, vs 88/uL with
plerixafor. Product content was twice as great with the combination
versus GCSF alone. The addition of plerixafor to GCSF more than
doubles the peak CD34 mobilization response and apheresis yield of
autologous PBSC collections in patients with PIDs and should greatly
facilitate PBSC-based treatment strategies.182
LONGER INCUBATION TIME OF FROZEN CORD BLOOD CFU-GM CUL-
TURES ALLOWS CELLS TO RECOVER AND SHOW SIMILAR GROWTH COM-
PARED TO CFU-GM ASSAYS PERFORMED ON FRESH CELLS
Stockinger, S., Flannery, S.,Miller, C.N.,Miller, S.N., Freed, B.M.Uni-
versity of Colorado, Aurora, CO
Assessment of cryopreserved umbilical cord blood potency is an
important criterion for hematopoietic stem cell engraftment.
